Ovid Therapeutics (OVID) Non-Current Deffered Revenue (2020)
Ovid Therapeutics (OVID) posted Non-Current Deffered Revenue of $10.2 million for Q4 2020, up 2.36% on a QoQ basis from $9.9 million in Q3 2020.
Ovid Therapeutics (OVID) Non-Current Deffered Revenue (2020) Analysis & Trends
Ovid Therapeutics' Non-Current Deffered Revenue history runs 1 years deep, the most recent figure standing at $10.2 million for Q4 2020.
- Quarterly Non-Current Deffered Revenue changed N/A year-over-year to $10.2 million in Q4 2020, while the trailing twelve-month figure through Dec 2020 was $10.2 million (changed N/A YoY) and the FY2020 annual result came in at $10.2 million, changed N/A from the prior year.
- Non-Current Deffered Revenue was $10.2 million for Q4 2020 at Ovid Therapeutics, up from $9.9 million in the prior quarter.
- Across five years, Non-Current Deffered Revenue topped out at $10.2 million in Q4 2020 and bottomed at $9.9 million in Q3 2020.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | - |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | 225.10 Mn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | - |
| 10 | Ovid Therapeutics | 118.66 Mn | -36.86 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2020 | 10.17 Mn |
| Sep 30, 2020 | 9.94 Mn |